Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.